MERCK HIV PROTEASE INHIBITOR TRIALS: HIGHER DOSE WILL BE TESTED
Executive Summary
MERCK HIV PROTEASE INHIBITOR TRIALS: HIGHER DOSE WILL BE TESTED in light of potential resistance that has emerged to L- 735,524 in early clinical trials, Merck said. Initial trials evaluated 400 mg four times daily. With the apparent emergence of resistance, Merck is proposing to increase the dose in the 60 patient Phase II study to 600 mg q.i.d.